サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1732961

肝炎診断検査市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、地域別、競合別、2020-2030年

Hepatitis Diagnostic Test Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By Region and Competition, 2020-2030F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=143.73円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

肝炎診断検査市場- 世界の産業規模、シェア、動向、機会、予測、検査タイプ別、地域別、競合別、2020-2030年
出版日: 2025年05月23日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界の肝炎診断検査市場は、2024年に45億8,000万米ドルと評価され、2030年には65億1,000万米ドルに達すると予測され、予測期間中のCAGRは6.04%で成長します。

肝炎、特にB型肝炎とC型肝炎の世界の有病率の増加が、正確でタイムリーな診断ソリューションの需要を促進しています。世界保健機関（WHO）によると、2021年には世界で3億2,500万人近くが慢性肝炎に罹患しており、効果的な診断介入が急務であることが浮き彫りになっています。この市場は、意識の高まり、技術の進歩、肝硬変やがんなどの合併症を予防するための早期発見の重要性によって活性化しています。血清検査、分子アッセイ、肝機能検査など、さまざまな検査法が利用可能になったことで、診断の幅が広がっています。さらに、革新的なポイントオブケア検査（POCT）機器により、特に遠隔地や十分なサービスを受けていない地域でも、診断がより身近なものとなっています。こうした進歩は、政府の取り組みや世界ヘルスキャンペーンの増加と相まって、市場の成長軌道を後押しし続けています。

市場概要
予測期間 2026-2030
市場規模：2024年 45億8,000万米ドル
市場規模：2030年 65億1,000万米ドル
CAGR：2025年～2030年 6.04%
急成長セグメント 血液検査
最大市場 北米

市場促進要因

世界の肝炎負担の増加

主な市場課題

高い診断コスト

主な市場動向

ポイントオブケア検査（POCT）

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 世界の肝炎診断検査市場展望

  • 市場規模・予測
    • 金額別
  • 市場シェア・予測
    • 検査の種類別（血液検査、画像検査、肝生検）
    • 地域別（北米、欧州、アジア太平洋、南米、中東・アフリカ）
    • 企業別（2024）
  • 製品市場マップ
    • テストタイプ別
    • 地域別

第6章 北米の肝炎診断検査市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 北米：国別分析
    • 米国
    • カナダ
    • メキシコ

第7章 欧州の肝炎診断検査市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 欧州：国別分析
    • ドイツ
    • フランス
    • 英国
    • イタリア
    • スペイン

第8章 アジア太平洋地域の肝炎診断検査市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • アジア太平洋地域：国別分析
    • 中国
    • 日本
    • インド
    • 韓国
    • オーストラリア

第9章 南米の肝炎診断検査市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第10章 中東・アフリカの肝炎診断検査市場展望

  • 市場規模・予測
  • 市場シェア・予測
  • 中東・アフリカ：国別分析
    • アラブ首長国連邦
    • サウジアラビア
    • 南アフリカ

第11章 市場力学

  • 促進要因
  • 課題

第12章 市場動向と発展

  • 合併と買収
  • 製品開発
  • 最近の動向

第13章 ポーター分析

第14章 PESTEL分析

第15章 競合情勢

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche AG
  • BioMerieux SA
  • Siemens Healthineers
  • Qiagen N.V.
  • Grifols SA
  • Fujirebio Inc.
  • Molbio diagnostics Pvt. Ltd
  • Meril LifeSciences Pvt. Ltd

第16章 戦略的提言

第17章 調査会社について・免責事項

目次
Product Code: 16280

The Global Hepatitis Diagnostic Test Market was valued at USD 4.58 billion in 2024 and is projected to reach USD 6.51 billion by 2030, growing at a CAGR of 6.04% during the forecast period. The increasing global prevalence of hepatitis, particularly Hepatitis B and C, is driving demand for accurate and timely diagnostic solutions. According to the World Health Organization, nearly 325 million individuals globally were living with chronic hepatitis in 2021, highlighting the urgent need for effective diagnostic interventions. This market is fueled by heightened awareness, technological advancements, and the importance of early detection to prevent complications like liver cirrhosis and cancer. The availability of various testing methods-including serology, molecular assays, and liver function tests-has broadened diagnostic capabilities. Furthermore, innovative point-of-care testing (POCT) devices are making diagnostics more accessible, especially in remote or underserved regions. These advancements, combined with increased government initiatives and global health campaigns, continue to bolster the market's growth trajectory.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 4.58 Billion
Market Size 2030USD 6.51 Billion
CAGR 2025-20306.04%
Fastest Growing SegmentBlood Tests
Largest MarketNorth America

Key Market Drivers

Rising Global Hepatitis Burden

The growing prevalence of hepatitis infections worldwide is a major force driving the Hepatitis Diagnostic Test Market. According to WHO, in 2023, approximately 60 million individuals in the South-East Asia region alone were living with chronic hepatitis B. Global transmission is often exacerbated by unsafe medical practices, lack of clean water and sanitation, and insufficient access to healthcare. Compounding this issue is the silent nature of hepatitis, which frequently progresses without symptoms until advanced liver damage has occurred. Early and accurate diagnosis is thus critical to preventing severe health outcomes such as cirrhosis and liver cancer. Governments and healthcare organizations are ramping up national screening programs and awareness campaigns, encouraging regular testing for high-risk populations including healthcare workers, people living with HIV, and intravenous drug users. These efforts are significantly expanding access to diagnostic services and promoting timely medical intervention.

Key Market Challenges

High Diagnostic Costs

A major challenge in the Hepatitis Diagnostic Test Market is the high cost associated with testing, particularly for molecular diagnostics such as PCR. These tests require specialized reagents, sophisticated equipment, and skilled laboratory personnel, which collectively drive up costs. This is especially burdensome in low-resource settings or among uninsured populations, where affordability becomes a barrier to widespread testing. Operational expenses tied to equipment maintenance, laboratory infrastructure, and quality assurance further increase the cost of diagnosis. Moreover, patients often require multiple tests to monitor disease progression and treatment efficacy, adding to the financial burden. In regions where insurance coverage is limited or inconsistent, out-of-pocket costs may deter individuals from undergoing necessary diagnostic evaluations.

Key Market Trends

Point-of-Care Testing (POCT)

Point-of-care testing is emerging as a transformative trend in hepatitis diagnostics. These compact, portable devices allow for rapid testing outside traditional laboratory environments, greatly enhancing diagnostic reach in rural and underserved areas. POCT minimizes the need for specialized equipment and skilled personnel, enabling quick, onsite diagnosis that facilitates timely treatment initiation. This immediacy not only improves patient outcomes but also helps curb the transmission of hepatitis within communities. The accessibility and speed of POCT make it a practical solution for widespread screening efforts, particularly in primary care settings and mobile health units. As healthcare providers seek more efficient and decentralized diagnostic methods, the adoption of POCT is expected to accelerate, driving market innovation and growth.

Key Market Players

  • Abbott Laboratories
  • Bio-Rad Laboratories Inc
  • F. Hoffmann-La Roche AG
  • BioMerieux SA
  • Siemens Healthineers
  • Qiagen N.V.
  • Grifols SA
  • Fujirebio Inc.
  • Molbio diagnostics Pvt. Ltd
  • Meril LifeSciences Pvt. Ltd

Report Scope:

In this report, the Global Hepatitis Diagnostic Test Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hepatitis Diagnostic Test Market, By Test Type:

  • Blood Tests
  • Imaging Test
  • Liver Biopsy

Hepatitis Diagnostic Test Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hepatitis Diagnostic Test Market.

Available Customizations:

Global Hepatitis Diagnostic Test market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Types
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, and Trends

4. Voice of Customer

5. Global Hepatitis Diagnostic Test Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Test Type (Blood Tests, Imaging Test, Liver Biopsy)
      • 5.2.1.1. By Blood Tests (Liver Function Tests, Immunoassays, Nucleic Acid Tests)
    • 5.2.2. By Region (North America, Europe, Asia Pacific, South America, Middle East & Africa)
    • 5.2.3. By Company (2024)
  • 5.3. Product Market Map
    • 5.3.1. By Test Type
    • 5.3.2. By Region

6. North America Hepatitis Diagnostic Test Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Test Type
    • 6.2.2. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Hepatitis Diagnostic Test Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Test Type
    • 6.3.2. Canada Hepatitis Diagnostic Test Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Test Type
    • 6.3.3. Mexico Hepatitis Diagnostic Test Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Test Type

7. Europe Hepatitis Diagnostic Test Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Test Type
    • 7.2.2. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Hepatitis Diagnostic Test Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Test Type
    • 7.3.2. France Hepatitis Diagnostic Test Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Test Type
    • 7.3.3. United Kingdom Hepatitis Diagnostic Test Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Test Type
    • 7.3.4. Italy Hepatitis Diagnostic Test Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Test Type
    • 7.3.5. Spain Hepatitis Diagnostic Test Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Test Type

8. Asia-Pacific Hepatitis Diagnostic Test Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Test Type
    • 8.2.2. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Hepatitis Diagnostic Test Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Test Type
    • 8.3.2. Japan Hepatitis Diagnostic Test Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Test Type
    • 8.3.3. India Hepatitis Diagnostic Test Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Test Type
    • 8.3.4. South Korea Hepatitis Diagnostic Test Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Test Type
    • 8.3.5. Australia Hepatitis Diagnostic Test Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Test Type

9. South America Hepatitis Diagnostic Test Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Test Type
    • 9.2.2. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Hepatitis Diagnostic Test Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Test Type
    • 9.3.2. Argentina Hepatitis Diagnostic Test Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Test Type
    • 9.3.3. Colombia Hepatitis Diagnostic Test Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Test Type

10. Middle East and Africa Hepatitis Diagnostic Test Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Test Type
    • 10.2.2. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. UAE Hepatitis Diagnostic Test Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Test Type
    • 10.3.2. Saudi Arabia Hepatitis Diagnostic Test Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Test Type
    • 10.3.3. South Africa Hepatitis Diagnostic Test Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Test Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition
  • 12.2. Product Development
  • 12.3. Recent Developments

13. Porter's analysis

14. PESTEL analysis

15. Competitive Landscape

  • 15.1. Abbott Laboratories
    • 15.1.1. Business Overview
    • 15.1.2. Company Snapshot
    • 15.1.3. Products & Services
    • 15.1.4. Financials (As Reported)
    • 15.1.5. Recent Developments
    • 15.1.6. Key Personnel Details
    • 15.1.7. SWOT Analysis
  • 15.2. Bio-Rad Laboratories Inc
  • 15.3. F. Hoffmann-La Roche AG
  • 15.4. BioMerieux SA
  • 15.5. Siemens Healthineers
  • 15.6. Qiagen N.V.
  • 15.7. Grifols SA
  • 15.8. Fujirebio Inc.
  • 15.9. Molbio diagnostics Pvt. Ltd
  • 15.10. Meril LifeSciences Pvt. Ltd

16. Strategic Recommendations

17. About Us & Disclaimers